Imhoff John E

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,662,756

F1 · price: On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.

SEC source: 0001477932-25-004137 · form4a.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.

SEC source: 0001477932-25-001072 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,762,756

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1593.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1593.

SEC source: 0001477932-24-008256 · form4.xml · derivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,615,385

Underlying: Common Stock · 1,615,385 shares

Expires 2028-12-17

F1 · kind: On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share.

F1 · price: On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share.

SEC source: 0001477932-24-008256 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,727,444

F1 · price: On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share.

SEC source: 0001477932-24-006671 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,112,059

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1556.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1556.

SEC source: 0001477932-24-006161 · form4.xml · derivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,666,667

Underlying: Common Stock · 1,666,667 shares

Expires 2028-09-22

F1 · kind: On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share.

F1 · price: On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share.

SEC source: 0001477932-24-006161 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,075,898

F1 · price: On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share.

SEC source: 0001477932-24-005207 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,409,231

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1093.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1093.

SEC source: 0001477932-24-005592 · form4.xml · derivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-07-30

F2 · kind: On July 31, 2024, the Company issued a $25,000 note payable to Mr. Imhoff. In conjunction with the note, the Company also issued four-year warrants to purchase an aggregate of 25,000 shares of Common Stock at $0.25 per share.

F2 · price: On July 31, 2024, the Company issued a $25,000 note payable to Mr. Imhoff. In conjunction with the note, the Company also issued four-year warrants to purchase an aggregate of 25,000 shares of Common Stock at $0.25 per share.

SEC source: 0001477932-24-004509 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,226,223

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1164.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1164.

SEC source: 0001477932-24-005592 · form4.xml · derivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 100,000 shares

Expires 2034-07-08

F1 · derivative.exercise_date: One-fourth of the shares subject to the award vested on July 9, 2024; the remaining shares will vest monthly, starting on October 9, 2024, subject to the reporting person's continued service on each such date, until the award is fully vested on July 8, 2027.

SEC source: 0001477932-24-002247 · form4.xml · nonDerivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,177,896

F2 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1157.

F2 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1157.

SEC source: 0001477932-24-002247 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,129,258

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.1361.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.1361.

SEC source: 0001477932-24-000856 · form4.xml · nonDerivative · entry 2

Imhoff John E · CIK 0001348439 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,124,838

F2 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1507.

F2 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1507.

SEC source: 0001477932-24-000856 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,087,514

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1504.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1504.

SEC source: 0001477932-23-006714 · form4.xml · nonDerivative · entry 3

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,050,104

F4 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1777.

F4 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1777.

SEC source: 0001477932-23-006714 · form4.xml · derivative · entry 4

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250

Underlying: Common Stock · 1,000,000 shares

Expires not disclosed

F2 · kind: These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3)).

F2 · price: These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3)).

F3 · derivative.expiration_date: These securities consist of Series E Convertible Preferred Stock ("Series E Preferred") of the Issuer that are presently convertible on a 1-for-4,000 basis into Common Stock without payment or further consideration. The Series E Preferred shares are convertible at any time until 8/21/2025. The Series E Preferred has no expiration date.

SEC source: 0001477932-23-006714 · form4.xml · nonDerivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,937,536

F2 · kind: These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3)).

F2 · price: These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3)).

SEC source: 0001477932-23-006714 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,436,637

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2139.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2139.

SEC source: 0001477932-23-004759 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,410,336

F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2512.

F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2512.

SEC source: 0001477932-23-004758 · form4.xml · derivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-02-09

F1 · price: One-fourth of the shares subject to the award vested on February 10, 2023; the remaining shares will vest monthly, subject to the reporting person's continued service on each such date, until the award is fully vested on February 9, 2026.

SEC source: 0001477932-23-004757 · form4.xml · nonDerivative · entry 1

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,356,532

F1 · price: On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Imhoff pursuant to which the Company issued 500,000 shares of its common stock, four-year warrants to purchase an aggregate of 500,000 shares of common stock for $0.50 per share and four-year warrants to purchase 500,000 shares of common stock for $0.65 per share for an aggregate purchase price of $250,000.

SEC source: 0001477932-23-004757 · form4.xml · derivative · entry 3

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2026-09-01

F1 · price: On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Imhoff pursuant to which the Company issued 500,000 shares of its common stock, four-year warrants to purchase an aggregate of 500,000 shares of common stock for $0.50 per share and four-year warrants to purchase 500,000 shares of common stock for $0.65 per share for an aggregate purchase price of $250,000.

SEC source: 0001477932-23-004757 · form4.xml · derivative · entry 2

Imhoff John E · CIK 0001348439 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2026-09-01

F1 · price: On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Imhoff pursuant to which the Company issued 500,000 shares of its common stock, four-year warrants to purchase an aggregate of 500,000 shares of common stock for $0.50 per share and four-year warrants to purchase 500,000 shares of common stock for $0.65 per share for an aggregate purchase price of $250,000.